We study the economic and political effects of competition by state-owned firms, leveraging the decentralized entry of public pharmacies to local markets in Chile around local elections. Public pharmacies sell drugs at a third of private pharmacy prices, because of a stronger upstream bargaining...

We study the effects of competition by state-owned firms, leveraging the decentralized entry of public pharmacies to local markets in Chile. Public pharmacies sell the same drugs at a third of private pharmacy prices, because of stronger upstream bargaining and market power in the private...

India has long been a central front in the struggle for access to affordable medicines. Because of its dynamic generic pharmaceutical industry, it has become what Médecins Sans Frontières has called the “Pharmacy of the Developing World” (MSF 2007). As a result, it has also been a key...

We analyze the financial performance of a hypothetical portfolio of 120 mRNA vaccine candidates in the preclinical stage targeting 11 emerging infectious diseases. We calibrate the simulation parameters with input from domain experts in mRNA technology and an extensive literature review. We find...

The theoretical relationship between market structure (number of firms) and conduct (pricing behavior) of the generic drug industry was investigated. The effects of qualitative variables such as therapeutic category, duration of use, popularity, and market entry aggressiveness on the...

The welfare implications of direct-to-consumer advertising (DTCA) have garnered considerable attention and are complicated since the consumer delegates some decision-making authority to the physician, who is exposed to advertising as well. In this paper, I develop and estimate a structural model...

Reference price regimes for prescription drugs are usually implemented with the aim of curbing public expenditure with pharmaceuticals, induce drug substitution from branded to generics drugs and enhance competition. In these systems, patients co-pay the difference between the drug's pharmacy...

Canada’s universal health insurance system leads to the under-provision of disease prevention by consumers. This paper demonstrates that a public health education campaign designed to increase coverage of preventive treatment can easily have the opposite effect. Using a model of targeted...

This paper explains how the current architecture of the pharmaceutical markets has created a misalignment of financial incentives and public health that is a central cause of harmful practices. It explores three possible solutions to address that misalignment: taxes, increased financial...

This paper analyses how governments can introduce more competition in the pharmaceutical sector. Considering it involves harmonizing issues such as incentives to innovate and perform research and development (R&D), Intellectual Property (IP) rights, healthcare policy and public budget concerns,...